Edwards Lifesciences Corporation

(New York Stock Exchange)
Back to all articles
Slightly Bearish -15

Edwards Lifesciences (EW) Stock Weighs DCF Fair Value Against High P/E Multiple - simplywall.st

AI-generated analysis

📊 DCF Model Valuation: The intrinsic value is estimated at $91.82 per share based on projected free cash flows extending to 2035.

💰 Current Price vs Intrinsic Value: The stock trades at $89.72, implying a small 2.3% undervaluation according to the DCF model.

📈 P/E Ratio Analysis: Edwards Lifesciences trades at a high multiple of 48.03x compared to a calculated Fair Ratio of 29.06x and an industry average of 24.97x.

🏥 Market Presence: The company provides technologies for treating advanced cardiovascular diseases in the US, Europe, Japan, and internationally.

📉 Valuation Check Score: The platform assigns a score of 1/6 on its valuation checks, citing high P/E multiples as a red flag.

🔮 Projection Data: Analyst estimates feed into the forecast with projected free cash flow reaching $1.93b for the year 2028.

🛠️ Investor Tools: The article promotes the platform's ability to create custom investment narratives using user-defined assumptions for revenue and margins.

Bullish Signals
  • The DCF model indicates the stock is technically undervalued by 2.3% relative to its estimated intrinsic value of $91.82.
  • The company operates in a global market providing advanced cardiovascular disease treatments across major regions including the US, Europe, and Japan.
Risk Factors
  • The stock trades at a P/E ratio of 48.03x, which is nearly double the calculated Fair Ratio of 29.06x and significantly higher than the industry average.
  • Simply Wall St's valuation check scores only 1 out of 6, explicitly flagging high P/E multiples as a red flag for investors.
Full Analysis
Simply Wall St's valuation analysis of Edwards Lifesciences (EW) indicates the stock is fairly valued based on a Discounted Cash Flow (DCF) model but appears overvalued relative to its P/E multiple. The DCF model, utilizing a two-stage free cash flow to equity approach with projections extending to 2035, estimates an intrinsic value of $91.82 per share against the recent trading price of $89.72. The analysis highlights a significant discrepancy in valuation metrics when comparing earnings multiples. Edwards Lifesciences currently trades at a P/E ratio of 48.03x, which is substantially higher than its calculated Fair Ratio of 29.06x and the industry average of approximately 25x. While the DCF suggests a minimal 2.3% undervaluation, the high multiple relative to peers and the proprietary fair value metric presents a conflicting signal regarding the stock's current pricing. The article notes that the company provides cardiovascular disease treatments in major markets including the US, Europe, and Japan. It concludes by suggesting that investors can utilize the platform's narrative tools to adjust assumptions for revenue and earnings to form their own buy or sell frameworks, as the provided analysis relies on historical data and analyst forecasts rather than real-time price-sensitive announcements.